Treatment with the class I HDAC inhibitor entinostat and IFNγ increased class II expression to 65.1% of cancer cells at 72 hours in 658 and doubled the effect of GSK126 at 24 hours (Fig. 5). This evidence concerns the gene HDAC9 and cancer.